Collateral Lethality: A new therapeutic strategy in oncology

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Genomic deletion of tumor suppressor genes (TSG) is common in human cancers.
• Synthetic lethality is a therapeutic strategy targeting TSG loss.
• Chromosomal proximity often leads to co-deletion of non-TSG (passenger) genes.

Purpose of the Study:

• To review the concept of collateral lethality.
• To highlight therapeutic vulnerabilities arising from co-deleted passenger genes.
• To explore opportunities for personalized anti-neoplastic therapies.

Main Methods:

• Review of the collateral lethality concept.
• Analysis of co-deletion events in cancer genomics.
• Identification of pharmacologically targetable vulnerabilities.

Main Results:

• Collateral lethality arises from co-deletion of passenger genes near TSGs.
• These passenger genes have diverse functions in cell homeostasis.
• Co-deletion creates cancer-specific vulnerabilities.

Conclusions:

• Collateral lethality offers a novel framework for cancer therapy development.
• Targeting collaterally deleted genes presents new avenues for personalized medicine.
• This approach expands the repertoire of actionable therapeutic targets in oncology.